Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC148610.15690/vramn1486RHEUMATOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ РЕВМАТОЛОГИИReview ArticleRole of Dendritic Cells in the Rheumatic Diseases Pathogenesis: ReviewРоль дендритных клеток в патогенезе ревматических заболеваний: обзор литературыhttps://orcid.org/0000-0002-7080-777X4897-2330KurochkinaYuliya D.КурочкинаЮлия Дмитриевна
Russian Federation

MD, PhD

к.м.н.

juli_k@bk.ruhttps://orcid.org/0000-0002-4890-08475494-7355KorolevMaxim A.КоролевМаксим Александрович
Russian Federation

MD, PhD

к.м.н.

kormax@bk.ruResearch Institute of Clinical and Experimental Lymphology, Affiliated Branch of Siberian Division of the Russian Academy of SciencesНаучно-исследовательский институт клинической и экспериментальной лимфологии — филиал Института цитологии и генетики Сибирского отделения Российской академии наук221020217643944012801202131082021Copyright ©; 2021, "Paediatrician" Publishers LLCCopyright ©; 2021, Издательство "Педиатръ"2021"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/1486

Dendritic cells (DCs) are professional antigen presenting cells that can as stimulate immune response as suppress immune inflamma tion. Recently the role of DCs in the pathogenesis of autoimmune diseases and the possibility of their application as diagnostic markers and methods of treatment has been studied more and more. It was shown that subpopulations DCs play different role in pathogenesis various autoimmune diseases. Thus, pathogenesis of rheumatoid arthritis and ankylosing spondylitis is associated with activity of myeloid DCs and their possibility to present arthritogenic peptides to T-cells. While plasmocytoid DCs are more important in pathogenesis systemic lupus erythematosus and systemic sclerosis. The review presents the results of the latest registered clinical trials about applications DCs in different autoimmune diseases as well as current ideas about functional features DCs during autoimmune diseases. The existing data confirm their possible use as well as the safety of DC in treatment.

Дендритные клетки (ДК) являются профессиональными антигенпрезентирующими клетками, способными как стимулировать иммунный ответ, так и подавлять иммунное воспаление. В последнее время все больше изучается роль ДК в патогенезе аутоиммунных заболеваний, а также исследуется возможность их применения в качестве маркеров диагностики и методов лечения. Показано, что в патогенезе различных заболеваний доминирующая роль отводится различным субпопуляциям ДК. Так, патогенез ревматоидного артрита и анкилозирующего спондилита связывают с активностью миелоидных ДК и их способностью презентировать артритогенные пептиды Т-лимфоцитам. В то же время в патогенезе системной красной волчанки и системного склероза определяющую роль играют плазмоцитоидные ДК. В обзоре представлены результаты последних зарегистрированных исследований по клиническому применению ДК при различных аутоиммунных заболеваниях, а также современные представления об их функциональных особенностях и роли в течении аутоиммунных заболеваний. Существующие данные подтверждают возможность их применения, а также безопасность ДК в лечении различных заболеваний.

dendrtitic cellsautoimmune diseasesrheumatoid arthritisдендритные клеткиаутоиммунные заболеванияревматоидный артритShortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007;7(1):19–30. doi: https://doi.org/10.1038/nri1996Langerhans P. Ueber die Nerven der menschlichen Haut. Archiv f Pathol Anat. 1868;44(2–3):325–337. doi: https://doi.org/10.1007/BF01959006Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142–1162.Merad M, Sathe P, Helft J, et al. The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting. Annu Rev Immunol. 2013;31(1):563–604. doi: https://doi.org/10.1146/annurev-immunol-020711-074950Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol. 2012;13(12):1145–1154. doi: https://doi.org/10.1038/ni.2467Cheong C, Matos I, Choi J-H, et al. Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas. Cell. 2010;143(3):416–429. doi: https://doi.org/10.1016/j.cell.2010.09.039Rhodes JW, Tong O, Harman AN, Turville SG. Human Dendritic Cell Subsets, Ontogeny, and Impact on HIV Infection. Front Immunol. 2019;10:1088. doi: https://doi.org/10.3389/fimmu.2019.01088Mbongue J, Nicholas D, Firek A, Langridge W. The Role of Dendritic Cells in Tissue-Specific Autoimmunity. J Immunol Res. 2014;2014:857143. doi: https://doi.org/10.1155/2014/857143Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23(1):975–1028. doi: https://doi.org/10.1146/annurev.immunol.22.012703.104538Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106(3):255–258. doi: https://doi.org/10.1016/s0092-8674(01)00449-4Hochweller K, Striegler J, Hämmerling GJ, Garbi N. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol. 2008;38(10):2776–2783. doi: https://doi.org/10.1002/eji.200838659Naranjo-Gómez M, Raïch-Regué D, Oñate C, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med. 2011;9(1):89. doi: https://doi.org/10.1186/1479-5876-9-89Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun. 2005;338(1):20–24. doi: https://doi.org/10.1016/j.bbrc.2005.08.232Terness P, Bauer TM, Röse L, et al. Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase-expressing Dendritic Cells. J Exp Med. 2002;196(4):447–457. doi: https://doi.org/10.1084/jem.20020052Maldonado RA, von Andrian UH. How Tolerogenic Dendritic Cells Induce Regulatory T Cells. Advances in Immunology. Alt FW, Austen KF, Honjo T, et al., eds. Academic Press; 2010. Р. 111–65. doi: https://doi.org/10.1016/B978-0-12-380995-7.00004-5Cassani B, Villablanca EJ, De Calisto J, et al. Vitamin A and immune regulation: Role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med. 2012;33(1):63–76. doi: https://doi.org/10.1016/j.mam.2011.11.001Zubizarreta I, Flórez-Grau G, Vila G, et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci. 2019;116(17):8463–8470. doi: https://doi.org/10.1073/pnas.1820039116Nikolic T, Zwaginga JJ, Uitbeijerse BS, et al. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide — for type 1 diabetes. Lancet Diabetes Endocrinol. 2020;8(6):470–472. doi: https://doi.org/10.1016/S2213-8587(20)30104-2Mosanya CH, Isaacs JD. Tolerising cellular therapies: what is their promise for autoimmune disease? Ann Rheum Dis. 2019;78(3):297–310. doi: https://doi.org/10.1136/annrheumdis-2018-214024Cauwels A, Tavernier J. Tolerizing Strategies for the Treatment of Autoimmune Diseases: From ex vivo to in vivo Strategies. Front Immunol. 2020;11:674. doi: https://doi.org/10.3389/fimmu.2020.00674Ness S, Lin S, Gordon JR. Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease. Front Immunol. 2021;12:633436. doi: https://doi.org/10.3389/fimmu.2021.633436Riazifar M, Mohammadi MR, Pone EJ, et al. Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. ACS Nano. 2019;13(6):6670–6688. doi: https://doi.org/10.1021/acsnano.9b01004Luque-Campos N, Contreras-López RA, Jose Paredes-Martínez M, et al. Mesenchymal Stem Cells Improve Rheumatoid Arthritis Progression by Controlling Memory T Cell Response. Front Immunol. 2019;10:798. doi: https://doi.org/10.3389/fimmu.2019.00798Chen Y, Yu Q, Hu Y, Shi Y. Current Research and Use of Mesenchymal Stem Cells in the Therapy of Autoimmune Diseases. Curr Stem Cell Res Ther. 2019;14(7):579–582. doi: https://doi.org/10.2174/1574888X14666190429141421Fischer UM, Harting MT, Jimenez F, et al. Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect. Stem Cells Dev. 2009;18(5):683–692. doi: https://doi.org/10.1089/scd.2008.0253Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659–672. doi: https://doi.org/10.1016/S0140-6736(09)60008-8Moret FM, Hack CE, van der Wurff-Jacobs KM, et al. Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity. Arthritis Res Ther. 2013;15(5):R155. doi: https://doi.org/10.1186/ar4338Kavousanaki M, Makrigiannakis A, Boumpas D, Verginis P. Novel role of plasmacytoid dendritic cells in humans: Induction of interleukin-10–producing treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum. 2010;62(1):53–63. doi: https://doi.org/10.1002/art.25037Lande R, Giacomini E, Serafini B, et al. Characterization and Recruitment of Plasmacytoid Dendritic Cells in Synovial Fluid and Tissue of Patients with Chronic Inflammatory Arthritis. J Immunol. 2004;173(4):2815–2824. doi: https://doi.org/10.4049/jimmunol.173.4.2815Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные // Научно-практическая ревматология. — 2019. — Т. 55. — № 4. — С. 452–461. [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):452–461. (In Russ.)] doi: https://doi.org/10.14412/1995-4484-2019-452-461Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62(12):3607–3614. doi: https://doi.org/10.1002/art.27702Raterman HG, Vosslamber S, de Ridder S, et al. Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14(2):R95. doi: https://doi.org/10.1186/ar3819Ramwadhdoebe TH, Ramos MI, Maijer KI, et al. Myeloid Dendritic Cells Are Enriched in Lymph Node Tissue of Early Rheumatoid Arthritis Patients but not in At Risk Individuals. Cells. 2019;8(7):756. doi: https://doi.org/10.3390/cells8070756Королев М.А., Курочкина Ю.Д., Банщикова Н.Е., и др. Особенности субпопуляционного состава дендритных клеток у больных ревматоидным артритом // Современная ревматология. — 2019. — Т. 13. — № 3. — С. 39–44. [Korolev MA, Kurochkina YD, Banshchikova NE, et al. Features of the subpopulation composition of dendritic cells in patients with rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;13(3):39–44. (In Russ.)] doi: https://doi.org/10/14412/1996-7012-2019-3-39-44Cooles FAH, Anderson AE, Skelton A, et al. Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis. Front Immunol. 2018;9:755. doi: https://doi.org/10.3389/fimmu.2018.00755Santiago-Schwarz F, Anand P, Liu S, Carsons SE. Dendritic Cells (DCs) in Rheumatoid Arthritis (RA): Progenitor Cells and Soluble Factors Contained in RA Synovial Fluid Yield a Subset of Myeloid DCs That Preferentially Activate Th1 Inflammatory-Type Responses. J Immunol. 2001;167(3):1758–1768. doi: https://doi.org/10.4049/jimmunol.167.3.1758Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39(4):437–446. doi: https://doi.org/10.1007/s00281-017-0627-zVerheul MK, Böhringer S, Delft MAM, et al. Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(11):1721–1731. doi: https://doi.org/10.1002/art.40562Savvateeva E, Smoldovskaya O, Feyzkhanova G, Rubina A. Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. Crit Rev Clin Lab Sci. 2021;58(1):17–28. doi: https://doi.org/10.1080/10408363.2020.1775545Grassia G, MacRitchie N, Platt AM, et al. Plasmacytoid dendritic cells: Biomarkers or potential therapeutic targets in atherosclerosis? Pharmacol Ther. 2013;137(2):172–182. doi: https://doi.org/10.1016/j.pharmthera.2012.10.001Фалалеева С.А., Курилин В.В., Шкаруба Н.С., и др. Характеристика подтипов дендритных клеток периферической крови у больных ревматоидным артритом // Медицинская иммунология. — 2013. — Т. 15. — № 4. — С. 343–350. [Falaleeva SA, Kurilin VV., Shkaruba NS, et al. Subtype characterics of dendritic cells from peripheral blood of patients with rheumatoid arthritis. Medical Immunology (Russia). 2014;15(4):343–350. (In Russ.)] doi: https://doi.org/10.15789/1563-0625-2013-4-343-350Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. 2015;74(6):1212–7121. doi: https://doi.org/10.1136/annrheumdis-2013-204960Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии // Научно-практическая ревматология. — 2018. — Т. 56. — № 3. — С. 263–271. [Nasonov EL, Olyunin YA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):263–271. (In Russ.)] doi: https://doi.org/10.14412/1995-4484-2018-263-271Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437. doi: https://doi.org/10.1136/annrheumdis-2016-209201Stoop JN, Harry RA, von Delwig A, et al. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 2010;62(12):3656–3665. doi: https://doi.org/10.1002/art.27756García-González P, Morales R, Hoyos L, et al. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J Transl Med. 2013;11(1):128. doi: https://doi.org/10.1186/1479-5876-11-128Benham H, Nel HJ, Law SC, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):290ra87. doi: https://doi.org/10.1126/scitranslmed.aaa9301Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76(1):227–234. doi: https://doi.org/10.1136/annrheumdis-2015-208456Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;301(7809):904–907. doi: https://doi.org/10.1016/s0140-6736(73)91360-3Faham M, Carlton V, Moorhead M, et al. Discovery of T Cell Receptor β Motifs Specific to HLA-B27-Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Arthritis Rheumatol. 2017;69(4):774–784. doi: https://doi.org/10.1002/art.40028Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nat Rev Rheumatol. 2017;13(6):359–367. doi: https://doi.org/10.1038/nrrheum.2017.56Paine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28(4):359–367. doi: https://doi.org/10.1097/BOR.0000000000000301Appel H, Maier R, Wu P, et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95. doi: https://doi.org/10.1186/ar3370Babaie F, Hasankhani M, Mohammadi H, et al. The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. Immunol Lett. 2018;196:52–62. doi: https://doi.org/10.1016/j.imlet.2018.01.014Wright PB, McEntegart A, McCarey D, et al. Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology. 2016;55(1):120–132. doi: https://doi.org/10.1093/rheumatology/kev245Talpin A, Costantino F, Bonilla N, et al. Monocyte-derived dendritic cells from HLA-B27+ axial spondyloarthritis (SpA) patients display altered functional capacity and deregulated gene expression. Arthritis Res Ther. 2014;16(4):417. doi: https://doi.org/10.1186/s13075-014-0417-0Pang L, Wang L, Suo T, et al. Tumor Necrosis Factor-α Blockade Leads to Decreased Peripheral T Cell Reactivity and Increased Dendritic Cell Number in Peripheral Blood of Patients with Ankylosing Spondylitis. J Rheumatol. 2008;35(11):2220–2228. doi: https://doi.org/10.3899/jrheum.080219Bertolini TB, Biswas M, Terhorst C, et al. Role of orally induced regulatory T cells in immunotherapy and tolerance. Cell Immunol. 2021;359:104251. doi: https://doi.org/10.1016/j.cellimm.2020.104251Liu G, Hao Y, Yang Q, Deng S. The Association of Fecal Microbiota in Ankylosing Spondylitis Cases with C-Reactive Protein and Erythrocyte Sedimentation Rate. Mediators Inflamm. 2020;2020: 8884324. doi: https://doi.org/10.1155/2020/8884324Системная красная волчанка // Ревматология: Российские клинические рекомендации / под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа; 2017. С. 113–141. [Sistemnaya krasnaya volchanka. Revmatologiya: Russian clinical guidelines. Nasonov EL, ed. Moscow: GEOTAR-Media; 2017. Р. 113–141. (In Russ.)]Santiago-Raber M-L, Baccala R, Haraldsson KM, et al. Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice. J Exp Med. 2003;197(6):777–788. doi: https://doi.org/10.1084/jem.20021996.Jørgensen TN, Roper E, Thurman JM, et al. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 × NZW)F1 mice. Genes Immun. 2007;8(8):653–662. doi: https://doi.org/10.1038/sj.gene.6364430Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69(2):376–386. doi: https://doi.org/10.1002/art.39962Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: https://doi.org/10.1136/lupus-2018-000286Соловьев С.К., Асеева Е.А., Попкова Т.В., и др. Системная красная волчанка: новые горизонты диагностики и терапии // Научно-практическая ревматология. — 2020. — Т. 58. — № 1. — С. 5–14. [Solovyev SK, Aseeva EA, Popkova TV, et al. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(1):5–14. (In Russ.)] doi: https://doi.org/10.14412/1995-4484-2020-5-14Rönnblom L, Alm GV. A Pivotal Role for the Natural Interferon α-producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus. J Exp Med. 2001;194(12):F59–F64. doi: https://doi.org/10.1084/jem.194.12.f59Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus. 2001;10(7):484–490. doi: https://doi.org/10.1191/096120301678416042Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115(2):407–417. doi: https://doi.org/10.1172/JCI23025Lepelletier Y, Zollinger R, Ghirelli C, et al. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood. 2010;116(18):3389–3397. doi: https://doi.org/10.1182/blood-2010-05-282913Carreño LJ, Pacheco R, Gutierrez MA, et al. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fcγ receptors and costimulatory molecules on dendritic cells. Immunology. 2009;128(3):334–341. doi: https://doi.org/10.1111/j.1365-2567.2009.03138.xFunes SC, Ríos M, Gómez-Santander F, et al. Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice. Immunology. 2019;158(4):322–339. doi: https://doi.org/10.1111/imm.13119Obreque J, Vega F, Torres A, et al. Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. Immunology. 2017;152(4):648–659. doi: https://doi.org/10.1111/imm.12806Ah Kioon MD, Tripodo C, Fernandez D, et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018;10(423):eaam8458. doi: https://doi.org/10.1126/scitranslmed.aam8458Volkmann ER, Tashkin DP, Roth MD, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016;18(1):305. doi: https://doi.org/10.1186/s13075-016-1203-yMehta H, Goulet P-O, Nguyen V, et al. Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis. Autoimmunity. 2016;49(8):503–513. doi: https://doi.org/10.1080/08916934.2016.1230848Kafaja S, Valera I, Divekar AA, et al. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight. 2018;3(9):e98380. doi: https://doi.org/10.1172/jci.insight.98380Chakraborty K, Chatterjee S, Bhattacharyya A. Modulation of CD11c+ lung dendritic cells in respect to TGF-β in experimental pulmonary fibrosis. Cell Biol Int. 2017;41(9):991–1000. doi: https://doi.org/10.1002/cbin.10800Ананьева Л.П., Тюрин И.Е., Конева О.А., и др. Интерстициальные заболевания легких при системном прогрессирующем склерозе (системной склеродермии) // Современная ревматология. — 2021. — Т. 15. — Прил. 1. — С. 1–62. [Ananyeva LP, Tyurin IE, Koneva OA, et al. Interstitial lung disease in systemic sclerosis (systemic scleroderma). Modern Rheumatology Journal. 2021;15(1S):1–62. (In Russ.)] doi: https://doi.org/10.14412/1996-7012-2021-1S-1-62Ананьева ЛП. Интерстициальное поражение легких, ассоциированное с системной склеродермией (прогрессирующим системным склерозом) // Научно-практическая ревматология. — 2017. — Т. 55. — № 1. — С. 87–95. [Ananyeva LP. Interstitial lung disease associated with systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):87–95. (In Russ.)] doi: https://doi.org/10.14412/1995-4484-2017-87-95Fancke B, Suter M, Hochrein H, O’Keeffe M. M-CSF: a novel plasmacytoid and conventional dendritic cell poietin. Blood. 2008;111(1):150–159. doi: https://doi.org/10.1182/blood-2007-05-089292Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63(11):3540–3546. doi: https://doi.org/10.1002/art.30548